Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Deciphering the multi-faceted roles of Afadin in breast cancer metastasis

FY 2022-23

Summary
Breast cancer is the most common cancer affecting women and is the second-leading cause of cancer-related deaths in these patients. The most destructive aspect of breast cancer occurs when the primary tumour spreads to distal organs/tissues through a process termed metastasis, most commonly to the lungs and liver. Indeed, as metastatic disease is responsible for 90% of all cancer-related deaths, it is critical that we advance our understanding regarding how cancer cells can metastasize. Leaving the primary tumour, entering the bloodstream, and colonizing a distal tissue requires significant restructuring of cell adhesions. In understanding how cancer cells acquire the ability to move, Dr. Peter Siegel’s research group has identified Afadin as an important contributor in this process. Interestingly, some studies suggest that this protein acts as a negative regulator, inhibiting the formation of distant metastasis. However, in a particular subtype of breast cancer, our results suggest that elevated Afadin levels in metastatic human breast tumours have poor metastasis-free and overall survival. Given the complex roles of Afadin, we are interested in investigating the cellular binding partners and resulting signalling networks that explain these seemingly opposing functions. To do so, we will sequentially eliminate protein domains within Afadin that allow it to exert its effect and observe the resulting changes to metastatic burden and location. As we investigate the cellular and molecular mechanisms of metastasis, information gathered will be used to devise new therapeutic strategies to treat patients with metastatic breast cancer.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
486053
Name
Vonniessen Benjamin
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Deciphering the multi-faceted roles of Afadin in breast cancer metastasis
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Breast Cancer; Cancer Cell Signalling; Functional Genomics; Liver Metastasis; Lung Metastasis; Pre-Clinical Models
Abstract
Breast cancer is the most common cancer affecting women and is the second-leading cause of cancer-related deaths in these patients. The most destructive aspect of breast cancer occurs when the primary tumour spreads to distal organs/tissues through a process termed metastasis, most commonly to the lungs and liver. Indeed, as metastatic disease is responsible for 90% of all cancer-related deaths, it is critical that we advance our understanding regarding how cancer cells can metastasize. Leaving the primary tumour, entering the bloodstream, and colonizing a distal tissue requires significant restructuring of cell adhesions. In understanding how cancer cells acquire the ability to move, Dr. Peter Siegel’s research group has identified Afadin as an important contributor in this process. Interestingly, some studies suggest that this protein acts as a negative regulator, inhibiting the formation of distant metastasis. However, in a particular subtype of breast cancer, our results suggest that elevated Afadin levels in metastatic human breast tumours have poor metastasis-free and overall survival. Given the complex roles of Afadin, we are interested in investigating the cellular binding partners and resulting signalling networks that explain these seemingly opposing functions. To do so, we will sequentially eliminate protein domains within Afadin that allow it to exert its effect and observe the resulting changes to metastatic burden and location. As we investigate the cellular and molecular mechanisms of metastasis, information gathered will be used to devise new therapeutic strategies to treat patients with metastatic breast cancer.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Vonniessen, Benjamin
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~